GoHealth (GOCO) – Resetting the Model for Sustainable Growth


Wednesday, April 01, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Results weaker than expected. Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million. 

Strategic reset. The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. At the same time, it has maintained leadership in Special Needs Plans (SNP), benefiting from carrier focus on high-need, high-retention populations. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The GLP-1 Race Goes Oral: FDA Approves Lilly’s Foundayo, Reshaping the Obesity Market and the Competitive Landscape

The FDA approved Eli Lilly’s (NYSE: LLY) Foundayo (orforglipron) today, a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related medical conditions. The approval marks a pivotal shift in one of the fastest-growing drug categories in history — and for small and microcap investors, the ripple effects are worth paying close attention to.

Foundayo joins Novo Nordisk’s Wegovy pill as the only two oral GLP-1 medications with FDA approval, but Lilly is positioning its drug as the more flexible option. Unlike the Wegovy pill, which must be taken in the morning 30 minutes before eating or drinking, Foundayo can be taken at any time of day and without restrictions on food and water.

It’s worth noting that Lilly is having one of the busiest 24-hour stretches in recent memory. Yesterday, the company announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $47.00 per share — a deal valued at approximately $7.8 billion — to bolster its neuroscience pipeline in sleep-wake disorders. [Related: Eli Lilly Banks $6.3 Billion on Sleep Science with Centessa Pharmaceuticals Acquisition] Today’s FDA approval underscores just how aggressively Lilly is moving across multiple therapeutic fronts simultaneously.

The Numbers Behind the Pill

In the ATTAIN-1 trial, patients receiving the highest dose who remained on treatment lost a mean of 27.3 pounds (12.4%) compared with 2.2 pounds (0.9%) among those receiving placebo. That’s meaningfully below the 20%+ weight loss seen with injectable GLP-1s like Zepbound, but Lilly isn’t positioning this as a replacement — it’s positioning it as an on-ramp.

Analysts estimate Foundayo sales will reach $14.79 billion by 2030, compared to expectations of $24.68 billion for Zepbound. On pricing, eligible people with commercial insurance may pay as little as $25 per month, self-pay patients can access it starting at $149 per month, and eligible Medicare Part D patients may access it for $50 per month beginning July 1, 2026.

The FDA reviewed the Foundayo application in just 50 days under a Commissioner’s National Priority Voucher pilot program, making it the fastest approval of a new molecular entity since 2002. That regulatory speed is its own headline.

What This Means for the Broader Market

The oral GLP-1 approval isn’t just a Lilly story — it’s a market structure story. Injectable GLP-1s built a massive but friction-filled market: cold storage requirements, weekly injection routines, and access barriers kept a significant portion of eligible patients on the sidelines. Fewer than 1 in 10 people who could benefit from a GLP-1 are currently taking one. A pill changes that calculus dramatically, and a larger addressable patient pool creates downstream opportunities across the healthcare ecosystem.

For smaller companies building in adjacent spaces — weight management technology platforms, metabolic disease diagnostics, complementary therapeutics — this approval accelerates the market they’re betting on. Novo Nordisk’s early data already suggests the pill is expanding the obesity treatment market rather than simply cannibalizing injectable demand, with more than 600,000 prescriptions for the Wegovy pill recorded in March alone.

The Competitive Pressure Is Real

Lilly’s approval also puts pressure on every company in the obesity space without an oral option. Novo has a head start on the pill market but carries the food and water restriction disadvantage. Other GLP-1 developers — many of them smaller biotechs — now face an even higher innovation bar. The era of “we have a GLP-1” being sufficient is over. Differentiation by mechanism, convenience, side effect profile, or patient population is now the only viable path to relevance.

Lilly expects Foundayo approval in more than 40 countries over the next year and has invested more than $55 billion in manufacturing since 2020 to support global scale — a moat that smaller competitors cannot easily replicate, making niche differentiation even more critical for emerging players.

The oral GLP-1 market is now officially open. The question for small and microcap investors is which companies are building the infrastructure, tools, and therapies that benefit from a world where obesity treatment becomes a daily pill.

Biogen Banks $5.6 Billion on Apellis as Big Pharma M&A Appetite for Biotech Heats Up

Biogen (Nasdaq: BIIB) is making its most consequential portfolio move in years, announcing a definitive agreement to acquire Apellis Pharmaceuticals (Nasdaq: APLS) for $41.00 per share in cash — an upfront equity consideration of approximately $5.6 billion — plus a contingent value right (CVR) tied to future sales milestones for its flagship eye disease therapy. The deal closed out March with a statement: big pharma is hungry, and specialty biotech is on the menu.

The transaction carries an 86% premium to Apellis’ 90-day volume-weighted average stock price and a 35% premium to its 52-week high. It is expected to close in the second quarter of 2026.

What Biogen Is Getting

At the center of the deal are two commercialized complement-targeting therapies: SYFOVRE® (pegcetacoplan injection), approved for geographic atrophy (GA) secondary to age-related macular degeneration, and EMPAVELI® (pegcetacoplan), approved across three rare immune-mediated conditions — C3 glomerulopathy (C3G), primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria (PNH).

Together, the two drugs generated $689 million in combined net product revenue in 2025, with growth expected in the mid-to-high teens annually through at least 2028. For a company navigating revenue headwinds from its legacy MS portfolio, that near-term visibility is exactly what Biogen needed.

SYFOVRE holds particular strategic weight as the first-ever approved therapy for geographic atrophy — a progressive retinal disease affecting more than five million people globally. Long-term efficacy data shows the drug can delay GA lesion progression by approximately 1.5 years in key patient populations, giving the asset durable commercial runway. The GA space is one that smaller innovators are also actively pursuing. Ocugen (Nasdaq: OCGN), is developing a gene therapy approach targeting inherited retinal diseases — the kind of differentiated, mechanism-driven science that has increasingly attracted large-cap attention.

The Nephrology Angle

Beyond the immediate revenue story, the strategic rationale runs deeper into kidney disease. Apellis brings an established nephrology sales infrastructure that Biogen intends to leverage for felzartamab, its Phase 3 kidney disease candidate with a first trial readout expected in the first half of 2027.

EMPAVELI’s rare kidney disease approvals — including the only FDA-approved treatment for pediatric patients with C3G and the first approval for post-transplant C3G recurrence — underscore how defensible rare nephrology positions can be. Two other emerging growth companies are staking ground in adjacent kidney disease spaces: Unicycive Therapeutics (Nasdaq: UNCY), developing oxylanthanum carbonate for hyperphosphatemia in chronic kidney disease patients, and Eledon Pharmaceuticals (Nasdaq: ELDN), advancing therapies focused on reducing kidney transplant rejection. The Biogen-Apellis deal reinforces that nephrology is becoming a high-value destination for large-cap dealmaking.

A Market Signal Worth Noting

The Apellis acquisition didn’t land in a vacuum. Earlier today, Eli Lilly announced a separate agreement to acquire Centessa Pharmaceuticals for up to $47.00 per share — a deal valued at approximately $7.8 billion including contingent payments — to bolster its neuroscience pipeline in sleep-wake disorders. Two major biotech acquisitions announced on the same day signals something broader: pharmaceutical companies with strong balance sheets are actively scanning for de-risked, commercially validated or late-stage assets, and they’re willing to pay premium prices to get them.

For investors tracking small and microcap biotech, that backdrop matters. Companies building real clinical differentiation in immunology, nephrology, and ophthalmology are operating in exactly the spaces that large pharma is now paying billions to enter.

CVR Structure and Financial Outlook

The CVR entitles Apellis shareholders to two potential payments of $2 per share, contingent on SYFOVRE hitting $1.5 billion and $2 billion in annual global net sales between 2027 and 2030. Biogen expects the deal to be increasingly accretive to non-GAAP diluted EPS starting in 2027, with full de-leveraging targeted by end of 2027.

Eli Lilly Invests $6.3 Billion on Sleep Science with Centessa Pharmaceuticals Acquisition

Eli Lilly (NYSE: LLY) is making one of its boldest neuroscience moves yet, announcing a definitive agreement to acquire clinical-stage biotech Centessa Pharmaceuticals (Nasdaq: CNTA) in a deal valued at up to $47.00 per share — representing a total potential equity value approaching $7.8 billion when contingent payments are included.

The upfront cash consideration of $38.00 per share reflects an aggregate equity value of approximately $6.3 billion and carries a 40.5% premium to Centessa’s 30-day volume-weighted average trading price ended March 30, 2026. Shareholders will also receive one non-transferable contingent value right (CVR) worth up to an additional $9.00 per share, tied to three FDA approval milestones for Centessa’s lead drug candidates.

What Lilly Is Really Buying

The deal is fundamentally about orexin receptor 2 (OX2R) science — a mechanism that sits at the neurobiological center of how the brain regulates the sleep-wake cycle. Centessa has spent years building what it believes is a potential best-in-class pipeline of OX2R agonists, with its lead candidate cleminorexton (formerly ORX750) having already shown promising Phase 2a clinical data across three major sleep disorders: narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

Beyond cleminorexton, Centessa’s portfolio includes additional clinical and preclinical-stage assets targeting neurological, neurodegenerative, and neuropsychiatric indications — giving Lilly a broader platform than a single drug acquisition would suggest.

The CVR Structure

The contingent value rights break down as follows: $2.00 per CVR upon FDA approval of cleminorexton or ORX142 for narcolepsy type 2 before the fifth anniversary of close; $5.00 per CVR upon FDA approval for idiopathic hypersomnia within the same window; and $2.00 per CVR upon the first FDA approval of either candidate for any indication before January 1, 2030.

CVR structures are increasingly common in biopharma M&A as a tool to bridge valuation gaps between buyers and sellers when clinical outcomes remain uncertain. For Centessa shareholders, the arrangement means meaningful upside if the pipeline delivers — but no guarantees.

Strategic Fit and Timing

The acquisition lands at a moment when sleep disorder therapeutics are gaining serious commercial momentum. The emergence of orexin-based therapies — like Idorsia’s daridorexant and Eisai and Biogen’s lemborexant — has validated the mechanism on the wake-promotion side of the equation. Centessa’s OX2R agonist approach works in the opposite direction, promoting wakefulness rather than suppressing it, which addresses a different and underserved patient population.

For Lilly, a company already navigating massive commercial demands from its GLP-1 and Alzheimer’s franchises, adding a differentiated neuroscience platform signals a commitment to diversifying its long-range pipeline.

The transaction is structured as a scheme of arrangement under English and Welsh law and is expected to close in the third quarter of 2026, pending Centessa shareholder approval, High Court sanction, and customary regulatory clearances. Approximately 24.1% of Centessa’s outstanding shares are already locked up through voting and support agreements signed by major investors including Medicxi Ventures, Index Ventures, and General Atlantic.

Unicycive Therapeutics (UNCY) – FY2025 Loss Reported With OLC PDUFA Data Approaching


Tuesday, March 31, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

NDA Sumisssion Was Accepted In January. Unicycive reported loss for FYQ25 of $26.6 million or $(1.67) per share. Importantly, the resubmission of the NDA for oxylanthanum calcium (OLC), its phosphate binder for controlling high phosphate levels in renal dialysis patients, was accepted for filing by the FDA. The PDUFA data is June 19, 2026. Cash on December 31, 2026 was $54.9 million, which we estimate is sufficient to last through product launch and the first quarter of OLC sales.

We Believe Previous Issues Have Been Settled. The NDA was submitted in December 2025 and accepted for filing in January. FDA acceptance and notification of the PDUFA date signifies that the application is complete for review. There were no questions about the third-party manufacturing issue that stopped the review process in June 2025. We believe the corrective actions have addressed the problem, allowing for marketing approval by June 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Iran’s Fifth Week: The Domino That Could Send Oil Prices Into Uncharted Territory

Oil markets opened the week in full crisis mode — and two developments over the weekend made clear that this conflict is far from finding a ceiling.

Brent crude traded near $108 per barrel Monday morning while WTI crossed $102, each up roughly 3% on the session and more than 70% above where they started the year. The war in Iran is now in its fifth week, and the supply picture just got significantly more complicated.

A Second Chokepoint Enters the Picture

The Strait of Hormuz has been effectively closed since early March, stripping roughly 20% of global oil and LNG supply from world markets in a single stroke. Saudi Arabia’s East-West Pipeline — the only meaningful rerouting option — is already running at its full capacity of 7 million barrels per day with zero room to expand.

Now a second chokepoint is under direct threat. Iran-backed Houthi militants in Yemen are positioning to disrupt the Bab el-Mandeb Strait — the narrow passage between Yemen and Djibouti that connects the Red Sea to the Gulf of Aden. Every westbound oil tanker that escapes Hormuz via Saudi Arabia’s pipeline must still transit this corridor to reach European and Atlantic markets. Insurance costs for Red Sea routes are climbing sharply and shipowners are already pulling back.

If the Bab el-Mandeb is closed, the market loses another estimated 7 million barrels per day — stacked on top of the 15 million already offline. That math would represent the most severe supply disruption in recorded energy history, eclipsing the 1973 oil shock in scale and speed.

Washington Raises the Stakes

The second driver of Monday’s move came from the White House. President Trump renewed explicit threats to destroy Iran’s oil infrastructure, power generation plants, and desalination facilities if a deal is not reached imminently. The U.S. now has approximately 50,000 troops deployed to the Gulf, including elite rapid-entry units. A Wall Street Journal report Sunday evening added that the administration is weighing a special operations mission to extract uranium from Iran’s underground nuclear compounds — a scenario that analysts broadly view as an immediate and severe escalation trigger.

Treasury Secretary Bessent offered a partial offset, hinting at potential U.S. or multinational naval escorts to restore navigation through the straits — which briefly pulled futures off their highs at Monday’s open. But the underlying tension held. Iran has continued to insist it is not in active negotiations, even as Trump has claimed “great progress” toward a deal.

JPMorgan’s commodities strategy team, led by Natasha Kaneva, wrote Sunday that markets are still underestimating the downside risks. The concern, they noted, is no longer whether this escalates further — it’s when.

The Broader Market Fallout

The energy crisis is metastasizing beyond the oil patch. European gas storage entered this conflict at historically low levels — roughly 30% capacity — after a harsh winter. Dutch TTF gas benchmarks have nearly doubled since hostilities began. Chemical and steel manufacturers across the UK and EU have imposed surcharges of up to 30% to offset surging input costs. The ECB has already postponed planned rate cuts and revised its inflation forecasts higher.

The International Energy Agency announced what would be the largest strategic petroleum reserve release in its history — 400 million barrels — as a near-term stabilizer. It addresses the pressure but not the cause. With two chokepoints now in play, no diplomatic resolution on the table, and 50,000 U.S. troops in the region, the structural bid under oil prices isn’t dissipating this week.

The energy industry’s own assessment is blunt: this may only be the beginning of the supply shock, not the peak of it.

FreightCar America (RAIL) – Updating Estimates; Rating Remains an Outperform


Monday, March 30, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating estimates. We revised our FY 2026 estimates to reflect lower margins in the first and second quarters. While our full year revenue, EBITDA, and EPS estimates are unchanged, the quarterly allocations have shifted. We forecast first quarter revenue, EBITDA, and EPS of $86.0 million, $7.0 million, and $0.04, respectively, compared to our prior estimates of $89.0 million, $8.8 million, and $0.08. We have assumed growing Aftermarket segment revenue throughout the year. Our FY 2026 revenue, EBITDA, and EPS estimates remain $525.0 million, $44.5 million, and $0.54, respectively. 

Lowering 1H’ 2026 expectations. We think the first quarter of 2026 will reflect the fewest deliveries during the year, along with a less favorable product mix. Accordingly, we expect 2026 deliveries, revenue, and earnings to be weighted toward the second half of the year, supported by higher volumes, an improved product mix, and increased contributions from new builds and retrofit programs.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Market Is Speaking in Two Languages Today — and Both Matter

Monday’s session delivered one of the cleanest market splits in recent weeks — energy surging, semiconductors cratering, and the major indexes going their separate ways as Wall Street entered a holiday-shortened trading week with no shortage of unresolved questions.

The Dow Jones added roughly 0.3% while the S&P 500 slipped 0.7% and the Nasdaq dropped nearly 1.1% by afternoon trading. Both the Dow and Nasdaq are now in correction territory following last week’s close. The divergence wasn’t noise — it reflected two very real and competing forces battling for the market’s direction.

The Chip Selloff Has a New Villain

Micron led semiconductor stocks sharply lower on Monday, falling more than 10% in afternoon trading. Sandisk shed 8%, Intel dropped 4%, AMD fell close to 3%, and Nvidia gave back roughly 1%. The across-the-board weakness extended a sell-off that began last week and found fresh fuel over the weekend.

The catalyst is a Google algorithm called TurboQuant, announced last week, which allows AI models to run more efficiently by cutting the amount of memory required. The implications for memory chip demand — and pricing — are exactly what the market is now attempting to price in. If AI workloads require meaningfully less memory bandwidth to operate, the demand thesis underpinning names like Micron gets complicated fast.

The debate is far from settled. Experts argue that memory chip pricing could stay firm through 2027, pointing to continued strength in AI data center demand with no signs of a slowdown and supply conditions tight enough to drive price inflation in several chip categories. That’s a reasonable counter — but on a Monday in a correction, the market is choosing the bearish read first and asking questions later.

Oil Doesn’t Care About Algorithms

On the other side of the ledger, crude had another strong session. Brent held above $107 per barrel and WTI crossed $103 as the Iran conflict continued to dominate commodity markets. President Trump added fresh fuel Monday, telling the Financial Times that his preference is for the U.S. to control Iran’s oil industry indefinitely — language that signals the conflict’s resolution is not imminent and that supply disruptions through the Strait of Hormuz and now the Bab el-Mandeb Strait could persist for weeks or months.

Energy was the one sector that didn’t need to rationalize its rally today. The math is straightforward: supply is constrained, no deal is in sight, and $100+ oil is becoming the baseline assumption rather than the shock scenario.

Eyes on the Week Ahead

With Friday’s session closed for Good Friday, this is a compressed week with outsized data. JOLTS, ADP private payrolls, and the March jobs report all land before the long weekend — and after the January-February whipsaw in employment numbers, each print carries extra weight. Nike’s earnings will offer a read on consumer health that the macro data alone can’t provide.

The setup: a market digesting a genuine technology disruption narrative while simultaneously pricing in the worst energy crisis in a generation. That’s not a market that moves in one direction.

Consumer Sentiment Just Hit a 3-Month Low

The American consumer is starting to crack, and the timing could not be worse for small-cap companies heading into earnings season.

The University of Michigan’s Index of Consumer Sentiment closed March at a final reading of 53.3 — below the 54 economists had forecast, down 5.8% from February, and the lowest reading since December. The drop was broad-based, cutting across all age groups and political affiliations, and it arrived just as small-cap stocks were already absorbing a brutal month of rising yields, a stalled rate-cut timeline, and a commodity shock with no clear end in sight.

The culprits are familiar by now: surging gas prices and stock market volatility tied directly to the Iran conflict. With the Strait of Hormuz still largely blocked and Brent crude trading above $110 per barrel, gas prices have risen more than $1 on average over the past month alone, according to AAA. That kind of increase hits consumers immediately and visibly — every fill-up is a reminder that something is wrong — and it has a well-documented drag on discretionary spending.

For small-cap companies, weakening consumer sentiment is not an abstract concern. These businesses — regional retailers, restaurant operators, consumer services companies, domestic manufacturers — are more directly exposed to shifts in consumer behavior than their large-cap counterparts, and they have fewer tools to manage the fallout. They can’t absorb margin compression as long, can’t hedge as efficiently, and don’t have the brand loyalty or pricing power that insulates household names from demand slowdowns.

The inflation expectations embedded in Friday’s data make the picture more complicated. Year-ahead inflation forecasts jumped to 3.8% from 3.4% in February — the largest single-month increase since April 2025, when sweeping global tariffs rattled markets. Long-term inflation expectations came in at 3.2%, still well above the pre-pandemic baseline. When consumers believe inflation is sticky, they pull back on big-ticket discretionary purchases and shift spending toward necessities. That behavioral shift flows directly into the revenue lines of the small-cap consumer sector.

There’s another dimension here that matters specifically to small-cap investors. Middle- and higher-income households reported some of the sharpest drops in sentiment this month, driven in part by stock market losses. With equity exposure now accounting for nearly 40% of household net worth — more than double its share during the oil shocks of the 1990s — market volatility has a faster and deeper psychological impact on consumer behavior than it did in previous energy crises. When portfolios fall, confidence follows, and discretionary spending follows confidence.

The S&P 500 is down 6.5% over the past month. The Dow is off 6.8%. The Russell 2000 has been even harder hit, entering correction territory earlier this month as the combination of higher-for-longer rates, a debt maturity wall, and energy-driven inflation converged at the worst possible time.

Consumer sentiment had been gradually recovering before March’s reversal, which means this isn’t a continuation of a trend — it’s a break in one. Whether it stabilizes or deteriorates further depends almost entirely on how long the Iran conflict persists and whether gas prices begin to pull back. Until there’s clarity on the Strait of Hormuz, small-cap consumer-facing companies should be approached with caution heading into Q1 earnings.

The data is speaking. The question is whether the market is listening.

$110 Oil and a Blocked Strait: The Iran Shock Is Now Splitting Small-Cap Stocks in Two

The Iran war didn’t just push Brent crude past $100 a barrel — it drew a sharp line through the small-cap market, separating companies that are printing cash from those quietly bleeding out. One month in, that divide just got wider.

Brent crude surged 2.82% to $111.06 per barrel on Friday after two ultra-large container vessels owned by China Ocean Shipping Company — COSCO, the world’s fourth-largest shipping line by capacity — attempted to transit the Strait of Hormuz and were turned back. The incident carries significant weight: China is an ally of Iran, and Tehran had previously signaled that friendly nations’ ships could pass freely. The fact that even Chinese vessels are being blocked signals that Iran’s chokehold on the waterway remains firmly in place, despite diplomatic noise suggesting otherwise.

Iran controls access to a strait that handles roughly 20% of the world’s daily oil supply. Since the U.S.-Israeli strikes began on February 28, close to 500 million barrels of total liquids have been lost, with approximately 17.8 million barrels per day of oil and fuel flows disrupted, according to Rystad Energy. WTI, meanwhile, climbed to $97.01 on Friday — up from roughly $65 in February. The buffer that kept prices from going completely vertical is now gone. Rystad’s chief oil analyst described the global supply system as having shifted from “buffered to fragile,” with inventories drawn down to a point where there is little room left to absorb further shocks.

President Trump announced a 10-day pause on strikes targeting Iran’s energy infrastructure through April 6, and said talks were progressing — but markets barely reacted. The COSCO incident hit the same day, effectively negating any diplomatic optimism. Iran also reportedly allowed 10 oil tankers to pass through the strait this week as a goodwill gesture, but analysts were quick to caution that isolated shipments do not signal a reopening.

The Winners: Domestic Producers and LNG Players

The clearest beneficiaries are U.S.-based exploration and production companies with no Middle East operational exposure. They’re capturing elevated prices without the liability of stranded tankers, damaged facilities, or rerouting costs eating into the margins of globally integrated operators.

Small- and mid-cap names like Antero Resources (AR), Solaris Energy Infrastructure (SEI), and SM Energy (SM) have all been flagged by analysts as well-positioned to benefit from both higher prices and the scramble among European and Asian buyers to replace Persian Gulf supply. Antero in particular benefits from the LNG export surge — Asian LNG prices have skyrocketed more than 140% since the war began as Qatar halted exports, and U.S. natural gas producers with export exposure are capturing that spread directly. The SPDR S&P Oil & Gas Exploration & Production ETF (XOP) is up roughly 10% since the conflict started, significantly outpacing the broader market.

The Losers: Everyone Paying the Energy Tax

For small-cap companies outside the energy sector, $110 oil is a cost, not a catalyst. Airlines, regional manufacturers, consumer discretionary companies, and logistics-heavy businesses are absorbing higher input costs with limited pricing power and thin margins. Unlike large-caps with robust balance sheets, smaller companies can’t easily hedge energy exposure or wait out a prolonged commodity spike.

The macro backdrop makes it worse. The Russell 2000 entered correction territory this month and the timing is brutal. Approximately 32% of the debt held by Russell 2000 companies is floating-rate, meaning every basis point that rate-cut expectations get pushed back translates directly into higher interest expenses. With the Fed holding rates steady at its March 18 meeting and revising its inflation outlook higher, the one rate cut markets were pricing in for late 2026 is increasingly in doubt. Small-cap firms are facing approximately $368 billion in debt maturing in 2026 alone, much of it originally issued at near-zero rates — now needing to be refinanced at 6.5% to 8%.

Bank of America has noted that small caps with oil exposure but limited refinancing risk may be best positioned in the current environment. That framing is the right lens heading into Q1 earnings. The question isn’t whether oil stays at $110. It’s whether your small-cap holdings are collecting the windfall or paying the price for it — and with the Strait of Hormuz turning away even Chinese vessels, there’s no telling when this resolves.

SKYX Platforms (SKYX) – Tempered Near-Term Outlook, Long-Term Scaling Remains


Friday, March 27, 2026

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results. SKYX reported revenue of $24.9M versus our $26.5M estimate, reflecting a modest miss tied to the delayed rollout of the SKYFAN & Turbo Heater and disruption from its new AI-driven e-commerce platform. Adj. EBITDA loss of $2.7M was worse than our expectation of a loss of $0.4M.

Near-term catalysts. The SKYFAN & Turbo Heater has launched across major retailers, and we expect broader distribution and SKU expansion to support growth through 2026. The new AI-driven platform should improve conversion across the company’s owned websites following near-term disruption.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Newsmax (NMAX) – Among The Few Media Growth Companies


Friday, March 27, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Exceeds Q4 results. Newsmax delivered solid fourth quarter results with total revenue of $52.2 million, representing a 9.6% year-over-year increase, driven primarily by growth in broadcasting revenue, particularly affiliate fees and linear advertising demand. Importantly, profitability trends improved meaningfully, with adjusted EBITDA outperforming expectations, reflecting early signs of operating leverage despite continued investment in content and infrastructure.

Quarter Highlights: The quarter was characterized by strong execution across key operating metrics, including robust affiliate fee growth (+17.9%), continued resilience in advertising revenue, and significant audience expansion across both linear and streaming platforms. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Google’s Memory Efficiency Breakthrough Sends Chip Stocks Tumbling — But Is the Market Overreacting?

Memory chip stocks took a beating Thursday after Google went public with research on a new algorithm that could dramatically reduce the amount of memory needed to run large language models — rattling a sector that had been riding an AI-fueled supply crunch straight up.

Samsung Electronics and SK Hynix, the South Korean heavyweights that dominate the high-bandwidth memory market, both fell at least 6% in Seoul trading. In the U.S., Micron Technology (MU) slid more than 7%, while Western Digital and Sandisk each dropped at least 5%. Nvidia (NVDA) was not spared either, shedding nearly 4% as broader AI infrastructure sentiment soured.

What Google Actually Did

Google’s TurboQuant algorithm, which the company publicized on X this week — though the underlying research originally surfaced last year — claims to cut the memory required to run large language models by at least a factor of six. The efficiency gain targets what’s known as the key value cache, a critical bottleneck in AI inference, or the process of running AI models to generate outputs.

If widely adopted, TurboQuant could reduce the memory footprint of AI workloads significantly, theoretically easing the supply crunch that has sent chip prices and margins soaring across the sector.

The Bull Case Didn’t Disappear Overnight

Context matters here. Memory chip stocks had been on an extraordinary run. SK Hynix and Samsung shares had each surged more than 50% year-to-date through Wednesday, fueled by insatiable demand from hyperscalers building out AI infrastructure at historic scale. SK Group Chairman Chey Tae-won as recently as this week said the memory chip shortage would persist through 2030.

Morgan Stanley analyst Shawn Kim pushed back on the panic in a note, arguing the impact of Google’s research should ultimately be net positive for the industry. His logic: if AI models can run with materially lower memory requirements without sacrificing performance, the cost per query drops, making AI deployment more profitable and accelerating adoption — which in turn drives more demand for memory, not less.

Kim and analysts at JPMorgan and Citigroup all invoked the Jevons Paradox — a 19th century economic concept holding that greater efficiency in resource use tends to increase total consumption rather than reduce it. The same argument made the rounds when DeepSeek’s low-cost AI model rattled markets last year.

The Bigger Picture for Investors

The four largest hyperscalers — led by Amazon and Google — are collectively on track to spend roughly $650 billion this year on data center infrastructure. That spending appetite doesn’t evaporate because of one efficiency algorithm, and Ortus Advisors analyst Andrew Jackson noted the Google development may make little practical difference to near-term demand given how constrained supply remains.

For small and microcap investors with exposure to the memory supply chain — component manufacturers, equipment makers, or specialty materials companies — Thursday’s selloff may be more noise than signal. The structural demand drivers behind AI infrastructure spending remain firmly intact.

The more pressing question isn’t whether TurboQuant reduces memory demand. It’s whether the market had already priced in perfection for a sector where any efficiency headline is now treated as an existential threat.